LONDON--(BUSINESS WIRE)--Technavio has announced their latest analysis report on drug pipeline for lipodystrophy syndrome. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat lipodystrophy syndrome.
This report by Technavio presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market in the future.
This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing
Lipodystrophy syndrome: Market overview
Lipodystrophy syndrome is a genetic or acquired rare disorder, which results in a fat loss (lipoatrophy) or an abnormal distribution/accumulation of fat tissues in the body. The severity of metabolic complications may determine the amount of fat loss. Lipodystrophy causes various metabolic complications such as insulin resistance, diabetes mellitus, hypertriglyceridemia, hepatic steatosis, and dyslipidemia.
According to a senior market research analyst at Technavio, “As per National Institute of Health, lipodystrophy is a rare disease. The familial partial lipodystrophy is estimated to be affecting one in one million people. Women are found to be more affected by familial partial lipodystrophy as compared to men.”
Lipodystrophy syndrome: Segmentation analysis
This pipeline analysis report segments the lipodystrophy syndrome market based on therapies employed (monotherapy), RoA (oral, subcutaneous, and intravenous+subcutaneous), therapeutic modality (biological, oligonucleotides, small molecule, and recombinant protein), targets (apolipoprotein C-III, leptin receptor, PPAR, ANGPTL3 protein, somatotropin receptor, and stearoyl-CoA desaturase), MoA (leptin receptor modulators, PPAR agonist, ANGPTL3 protein inhibitors, apolipoprotein C-III inhibitors, gene silencing, somatotropin receptor agonists, and stearoyl-CoA desaturase modulators), geographical segmentation (US and Belgium) and recruitment status (active, not recruiting and recruiting). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.
Based on therapeutic modality, more than 33% of the molecules that are being investigated for the treatment of lipodystrophy syndrome are biological molecules.
Looking for more information on this market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Regulatory Framework
Drug Development Landscape
- Drugs under development
- Indications coverage
Drug Development Strategies
- Therapies employed
- RoA
- Therapeutic modality
- Geographical coverage
Recruitment Strategies
- Recruitment status
- Gender
- Age
Key Companies
- Type of players
- Company overview
Discontinued or Dormant Molecules
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at media@technavio.com.
